唑来膦酸辅助治疗与绝经状态。
Adjuvant therapy with zoledronic Acid and menopausal status.
出版信息
Oncologist. 2013;18(8):e24. doi: 10.1634/theoncologist.2013-0109.
Abstract
Zoledronic acid as adjuvant therapy in breast cancer patients has been shown to have a beneficial effect on OS. Adjuvant treatment with clodronate also may improve OS in patients with early breast cancer. Further study with analysis of subgroups by age or menopausal status should be performed to investigate adjuvant therapy with bisphosphonates in breast cancer patients.
摘要
唑来膦酸作为乳腺癌患者的辅助治疗已被证明对 OS 有有益影响。用氯膦酸盐进行辅助治疗也可能改善早期乳腺癌患者的 OS。应进行进一步的研究，通过年龄或绝经状态亚组分析，以研究乳腺癌患者用双磷酸盐进行辅助治疗。
相似文献
1
Adjuvant therapy with zoledronic Acid and menopausal status.唑来膦酸辅助治疗与绝经状态。
Oncologist. 2013;18(8):e24. doi: 10.1634/theoncologist.2013-0109.
2
Zoledronic acid and its accentuating effect on tumor radiosensitivity.唑来膦酸及其对肿瘤放射敏感性的增强作用。
Oncologist. 2013;18(8):e21. doi: 10.1634/theoncologist.2013-0054.
3
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.唑来膦酸辅助治疗乳腺癌患者的系统评价和荟萃分析。
Oncologist. 2013;18(4):353-61. doi: 10.1634/theoncologist.2012-0261. Epub 2013 Feb 12.
4
In reply.回复。
Oncologist. 2013;18(8):e26-7. doi: 10.1634/theoncologist.2013-0235.
5
Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer.医学肿瘤学：唑来膦酸可预防早期乳腺癌患者的骨质流失。
Nat Rev Clin Oncol. 2009 Apr;6(4):191-2. doi: 10.1038/nrclinonc.2009.24.
6
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.绝经前早期乳腺癌患者辅助内分泌治疗联合唑来膦酸：ABCSG-12骨密度亚研究的5年随访
Lancet Oncol. 2008 Sep;9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19.
7
Role of zoledronate in aromatase activity should be considered in future studies.唑来膦酸在芳香化酶活性中的作用应在未来的研究中加以考虑。
Oncologist. 2013;18(8):e25. doi: 10.1634/theoncologist.2013-0208.
8
γδ T cells predict outcome in zoledronate-treated breast cancer patients.γδ T 细胞可预测唑来膦酸盐治疗的乳腺癌患者的预后。
Oncologist. 2013;18(8):e22-3. doi: 10.1634/theoncologist.2013-0097.
9
S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer.S0307. 双膦酸盐作为原发性乳腺癌辅助治疗的III期试验。
Clin Adv Hematol Oncol. 2005 Nov;3(11):852-4.
10
The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.唑来膦酸在乳腺癌辅助治疗中的作用：当前观点。
Expert Opin Pharmacother. 2010 Nov;11(16):2715-25. doi: 10.1517/14656566.2010.523699.
本文引用的文献
1
Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: results from an updated systematic review and meta-analysis.口服辅助氯膦酸盐治疗可改善早期乳腺癌的总生存：一项更新的系统评价和荟萃分析结果。
Eur J Cancer. 2013 Jun;49(9):2086-92. doi: 10.1016/j.ejca.2013.01.021. Epub 2013 Feb 26.
2
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.唑来膦酸辅助治疗乳腺癌患者的系统评价和荟萃分析。
Oncologist. 2013;18(4):353-61. doi: 10.1634/theoncologist.2012-0261. Epub 2013 Feb 12.
3
The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.唑来膦酸在乳腺癌辅助治疗中的疗效：一项随机对照试验的荟萃分析。
Eur J Cancer. 2012 Jan;48(2):187-95. doi: 10.1016/j.ejca.2011.10.021. Epub 2011 Nov 17.
4
Breast-cancer adjuvant therapy with zoledronic acid.唑来膦酸辅助治疗乳腺癌。
N Engl J Med. 2011 Oct 13;365(15):1396-405. doi: 10.1056/NEJMoa1105195. Epub 2011 Sep 25.
5
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.辅助内分泌治疗联合唑来膦酸治疗早期乳腺癌绝经前妇女：ABCGS-12 随机试验的 62 个月随访结果。
Lancet Oncol. 2011 Jul;12(7):631-41. doi: 10.1016/S1470-2045(11)70122-X. Epub 2011 Jun 5.
6
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.唑来膦酸在接受辅助来曲唑治疗的绝经后早期乳腺癌妇女中的疗效：ZO-FAST 研究的 36 个月结果。
Ann Oncol. 2010 Nov;21(11):2188-2194. doi: 10.1093/annonc/mdq217. Epub 2010 May 5.
Zotero 插件